do not combine dpp-4 inhibitors with glp-1 receptor agonists guidance GLP-1-RA and in the management of type 2 diabetes The effect of DPP-4 inhibitors,
Description
So its a case of leapfrogging and iterative improvement

T., Laven, J

Safety signals in specific populations, insufficient efficacy in certain endpoints, or manufacturing challenges could all slow progress
00174-1/asset/4ff9bb50-3a8f-4946-a683-db1579705072/main.assets/gr1.jpg)
Glucagon-like peptide 1 receptor agonists and heart failure: The need for further evidence generation and practice guidelines optimization

Clinical interest has focused on GLP-1 as GIP is no longer active in Type 2 diabetes
Muscle Mass Reduction Studies indicate that up to 40% of weight loss on some GLP-1 medications can actually be lean muscle rather than fat tissue
